Paz, K;
Flynn, R;
Du, J;
Tannheimer, S;
Johnson, AJ;
Dong, S;
Stark, A-K;
... Blazar, BR; + view all
(2019)
Targeting PI3Kδ function for amelioration of murine chronic graft‐versus‐host disease.
American Journal of Transplantation
, 19
(6)
pp. 1820-1830.
10.1111/ajt.15305.
Preview |
Text
Paz_et_al-Blazar_2019-American_Journal_of_Transplantation.pdf - Accepted Version Download (634kB) | Preview |
Abstract
Chronic graft‐versus‐host disease (cGVHD) is a leading cause of morbidity and mortality following allotransplant. Activated donor effector T cells can differentiate into pathogenic T helper (Th)‐17 cells and germinal center (GC)–promoting T follicular helper (Tfh) cells, resulting in cGVHD. Phosphoinositide‐3‐kinase‐δ (PI3Kδ), a lipid kinase, is critical for activated T cell survival, proliferation, differentiation, and metabolism. We demonstrate PI3Kδ activity in donor T cells that become Tfh cells is required for cGVHD in a nonsclerodermatous multiorgan system disease model that includes bronchiolitis obliterans (BO), dependent upon GC B cells, Tfhs, and counterbalanced by T follicular regulatory cells, each requiring PI3Kδ signaling for function and survival. Although B cells rely on PI3Kδ pathway signaling and GC formation is disrupted resulting in a substantial decrease in Ig production, PI3Kδ kinase‐dead mutant donor bone marrow–derived GC B cells still supported BO cGVHD generation. A PI3Kδ‐specific inhibitor, compound GS‐649443, that has superior potency to idelalisib while maintaining selectivity, reduced cGVHD in mice with active disease. In a Th1‐dependent and Th17‐associated scleroderma model, GS‐649443 effectively treated mice with active cGVHD. These data provide a foundation for clinical trials of US Food and Drug Administration (FDA)–approved PI3Kδ inhibitors for cGVHD therapy in patients.
| Type: | Article |
|---|---|
| Title: | Targeting PI3Kδ function for amelioration of murine chronic graft‐versus‐host disease |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1111/ajt.15305 |
| Publisher version: | https://doi.org/10.1111/ajt.15305 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | basic (laboratory) research/science, graft‐versus‐host disease (GVHD), immunobiology, immunosuppressant ‐ other |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10068844 |
Archive Staff Only
 |
View Item |
